632 related articles for article (PubMed ID: 36056434)
41. A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection.
Molparia B; Oliveira G; Wagner JL; Spencer EG; Torkamani A
PLoS One; 2018; 13(5):e0196826. PubMed ID: 29791457
[TBL] [Abstract][Full Text] [Related]
42. A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer.
Wu X; Zhang Y; Hu T; He X; Zou Y; Deng Q; Ke J; Lian L; He X; Zhao D; Cai X; Chen Z; Wu X; Fan JB; Gao F; Lan P
Mol Oncol; 2021 Oct; 15(10):2702-2714. PubMed ID: 33694305
[TBL] [Abstract][Full Text] [Related]
43. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood.
Kresse SH; Brandt-Winge S; Pharo H; Flatin BTB; Jeanmougin M; Vedeld HM; Lind GE
Clin Epigenetics; 2023 Sep; 15(1):151. PubMed ID: 37710283
[TBL] [Abstract][Full Text] [Related]
45. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
46. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
Petrillo A; Salati M; Trapani D; Ghidini M
Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
[TBL] [Abstract][Full Text] [Related]
47. Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer.
Morris VK; Strickler JH
Annu Rev Med; 2021 Jan; 72():399-413. PubMed ID: 33502901
[TBL] [Abstract][Full Text] [Related]
48. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
[TBL] [Abstract][Full Text] [Related]
49. Liquid biopsy in colorectal cancer: Onward and upward.
Torresan S; de Scordilli M; Bortolot M; Di Nardo P; Foltran L; Fumagalli A; Guardascione M; Ongaro E; Puglisi F
Crit Rev Oncol Hematol; 2024 Feb; 194():104242. PubMed ID: 38128627
[TBL] [Abstract][Full Text] [Related]
50. Liquid biopsy in Retinoblastoma: A review.
Ghose N; Kaliki S
Semin Ophthalmol; 2022; 37(7-8):813-819. PubMed ID: 35604935
[TBL] [Abstract][Full Text] [Related]
51. Enhanced detection of circulating tumor DNA by fragment size analysis.
Mouliere F; Chandrananda D; Piskorz AM; Moore EK; Morris J; Ahlborn LB; Mair R; Goranova T; Marass F; Heider K; Wan JCM; Supernat A; Hudecova I; Gounaris I; Ros S; Jimenez-Linan M; Garcia-Corbacho J; Patel K; Østrup O; Murphy S; Eldridge MD; Gale D; Stewart GD; Burge J; Cooper WN; van der Heijden MS; Massie CE; Watts C; Corrie P; Pacey S; Brindle KM; Baird RD; Mau-Sørensen M; Parkinson CA; Smith CG; Brenton JD; Rosenfeld N
Sci Transl Med; 2018 Nov; 10(466):. PubMed ID: 30404863
[TBL] [Abstract][Full Text] [Related]
52. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
53. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
54. Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma.
Nguyen MTN; Rajavuori A; Huhtinen K; Hietanen S; Hynninen J; Oikkonen J; Hautaniemi S
Biomed Pharmacother; 2023 Dec; 168():115630. PubMed ID: 37806091
[TBL] [Abstract][Full Text] [Related]
55. Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA.
Yeh YM; Lin PC; Lee CT; Chen SH; Lin BW; Lin SC; Chen PC; Chan RH; Shen MR
Mol Cancer; 2020 Oct; 19(1):150. PubMed ID: 33106181
[TBL] [Abstract][Full Text] [Related]
56. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
[TBL] [Abstract][Full Text] [Related]
57. Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
Stankunaite R; George SL; Gallagher L; Jamal S; Shaikh R; Yuan L; Hughes D; Proszek PZ; Carter P; Pietka G; Heide T; James C; Tari H; Lynn C; Jain N; Portela LR; Rogers T; Vaidya SJ; Chisholm JC; Carceller F; Szychot E; Mandeville H; Angelini P; Jesudason AB; Jackson M; Marshall LV; Gatz SA; Anderson J; Sottoriva A; Chesler L; Hubank M
Eur J Cancer; 2022 Feb; 162():209-220. PubMed ID: 34933802
[TBL] [Abstract][Full Text] [Related]
58. Enhanced Detection of Genitourinary Cancers Using Fragmentation and Copy Number Profiles Obtained from Urinary Cell-Free DNA.
Han Y; Li X; Zhang M; Yang Y; Ge G; Wang K; Gong Y; Liang Y; Niu H; Ci W
Clin Chem; 2021 Jan; 67(2):394-403. PubMed ID: 33523215
[TBL] [Abstract][Full Text] [Related]
59. Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management.
Hallermayr A; Steinke-Lange V; Vogelsang H; Rentsch M; de Wit M; Haberl C; Holinski-Feder E; Pickl JMA
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159118
[TBL] [Abstract][Full Text] [Related]
60. Aberrant circulating tumor DNA methylation and exosomal microRNA biomarkers for early detection of colorectal cancer.
Zhang X; Hou H; Jiang M; Zhang X
Mol Biol Rep; 2023 Mar; 50(3):2743-2750. PubMed ID: 36583782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
